Section Arrow
Quote
REGN.NASDAQ
- Regeneron Pharmaceuticals
Quotes are at least 15-min delayed:2024/06/24 08:22 EDT
Last
 1,053.305
+8.915 (+0.85%)
Day High 
1,059.8 
Prev. Close
1,044.39 
1-M High
1,052.34 
Volume 
1.29M 
Bid
1,030
Ask
1,128
Day Low
1,041.25 
Open
1,047.71 
1-M Low
952.3 
Market Cap 
115.08B 
Currency USD 
P/E 30.84 
%Yield 0 
10-SMA 1,023.56 
20-SMA 1,003.17 
50-SMA 961.52 
52-W High 1,059.8 
52-W Low 684.805 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
33.87/48.57
Enterprise Value
117.78B
Balance Sheet
Book Value Per Share
244.96
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
13.12B
Operating Revenue Per Share
118.87
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
MBIOMustang Bio0.5594-0.0011-0.20%-- 
DNAGinkgo Bioworks Holdings0.4244+0.0157+3.84%-- 
KTRAKintara Therapeutics0.2472-0.0277-10.08%-- 
BMRNBioMarin Pharmaceutical83.72-0.99-1.17%79.92PE
QLGNQualigen Therapeutics0.222+0.0449+25.35%-- 
Quotes are at least 15-min delayed：2024/06/24 08:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.